SCHEMBL25001074

SCHEMBL25001074

COc1ccc(N)c(OC(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.35
NNMT P40261 2/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
PIK3CA P42336 1/20 0.34
F10 P00742 2/20 0.33
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
ST14 Q9Y5Y6 1/20 0.33
PLAU P00749 1/20 0.32
CYP1A2 P05177 1/20 0.31
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30168387 1.00 POLB (0.39) POLBTDP1KDM4ENNMTSIRT2
SCHEMBL30271349 0.88 NNMT (0.33) NNMTF10F2PRSS1PRSS2
SCHEMBL29830254 0.86 POLB (0.35) POLBTDP1KDM4EPIK3CAF10
SCHEMBL23620230 0.86 POLB (0.35) POLBTDP1KDM4EPIK3CAF10
SCHEMBL25000973 0.84 PDE10A (0.40) POLBTDP1NNMTSIRT2SIRT1
SCHEMBL30271360 0.81 ALDH1A1 (0.35) POLBTDP1KDM4EPIK3CAF10
SCHEMBL656848 0.81 POLB (0.50) POLBTDP1NNMTSIRT2SIRT1
SCHEMBL30054640 0.81 POLB (0.50) POLBTDP1NNMTSIRT2SIRT1
Hydrochloric Acid SCHEMBL930533 0.79 POLB (0.48) POLBTDP1NNMTSIRT2SIRT1
SCHEMBL23620227 0.78 POLB (0.36) POLBTDP1NNMTSIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4654965-A1 CRYSTALLINE COMPOUND OF AN LPAR1 ANTAGONIST Contineum Therapeutics, Inc. (US) 2025-12-03 EP disclosed
US-20250179045-A1 LPAR1 ANTAGONISTS AND USES THEREOF CONTINEUM THERAPEUTICS, INC. 2025-06-05 US disclosed
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 US disclosed
WO-2024159176-A1 CRYSTALLINE COMPOUND OF AN LPAR1 ANTAGONIST CONTINEUM THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
CN-118043041-A LPAR1 antagonists and uses thereof 康蒂内乌姆医疗公司 2024-05-14 CN disclosed
WO-2023014907-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2023014907-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed
WO-2023014908-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. (US) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179045-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 POLB 4089/4885TDP1 3301/4885KDM4E 4637/4885
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 POLB 4089/4885TDP1 3301/4885KDM4E 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.